NCT01261481View on ClinicalTrials.gov

Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

February 29, 2012

Conditions
Healthy
Interventions
DRUG

Tolvaptan

Tolvaptan 15 mg administered once orally as an intact tablet.

DRUG

Tolvaptan

Tolvaptan 15 mg administered once via nasogastric tube.

Trial Locations (1)

27599

University of North Carolina Healthcare, Chapel Hill

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER